RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000084.xml
Synthesis 2006(22): 3835-3840
DOI: 10.1055/s-2006-950330
DOI: 10.1055/s-2006-950330
PAPER
© Georg Thieme Verlag Stuttgart · New York
Syntheses of 5-Fluoro and (E)-5-(2-Fluorovinyl) Arabinosyl Uridine Analogues as Potential Probes for the HSV-1 Thymidine Kinase Gene
Weitere Informationen
Received
20 April 2006
Publikationsdatum:
20. Oktober 2006 (online)
Publikationsverlauf
Publikationsdatum:
20. Oktober 2006 (online)
Abstract
The syntheses of 5-fluoro (FaraU) and (E)-5-(2-fluorovinyl) arabinosyl uridine (FVAU) via 5-trimethylstannyl and (E)-5-(2-tributylstannylvinyl) arabinosyl uridine analogues with selectfluor is described. Boc protection of the uridine moiety improved the yield of synthesis and differences between N-Boc and O-Boc isomers were established by 1H- and 13C NMR. The Boc-protected stannyl intermediates may be fluorinated with 18F to produce [18F]FaraU and [18F]FVAU.
Key words
stannane - fluoro - arabinosyl - cancer - gene therapy
- For reviews, see:
-
1a
Peñuelas I.Boán JF.Martí-Climent JM.Sangro B.Mazzolini G.Prieto J.Richter JA. Mol. Imaging Biol. 2004, 6: 225 -
1b
Herschman HR. Crit. Rev. Oncol. Hematol. 2004, 51: 191 -
1c
Herschman HR. J. Cell. Biochem. Suppl. 2002, 39: 36 -
1d
Advani SJ.Weichselbaum RR.Whitley RJ.Roizman B. Clin. Microbiol. Infect. 2002, 8: 551 -
2a
de Vries EFJ.Buursma AR.Hospers GAP.Mulder NH.Vaalburg W. Curr. Pharm. Des. 2002, 8: 1435 -
2b
Gambhir SS.Herschman HR.Cherry SR.Barrio JR.Satyamurthy N.Toyokuni T.Phelps ME.Larson SM.Balatoni J.Finn R.Sadelain M.Tjuvajev J.Blasberg R. Neoplasia 2000, 2: 118 -
2c
Nichol C.Kim EE. J. Nucl. Med. 2001, 42: 1368 -
2d
Gibson RE.Burns HD.Hamill TG.Eng WS.Francis BE.Ryan C. Curr. Pharm. Des. 2000, 6: 973 - 3
Verel I.Visser GWM.Vosjan MJWD.Finn R.Boellaard R.van Dongen GAMS. Eur. J. Nucl. Med. Mol. Imaging 2004, 31: 1645 - 4
Green LA.Nguyen K.Berenji B.Iyer M.Bauer E.Barrio JR.Namavari M.Satyamurthy N.Gambhir SS. J. Nucl. Med. 2004, 45: 1560 - For [18F]-FHBG, see:
-
5a
Yaghoubi SS.Barrio JR.Namavari M.Satyamurthy N.Phelps ME.Herschman HR.Gambhir SS. Cancer Gene Ther. 2005, 12: 329 -
5b
Ponde DE.Dence CS.Schuster DP.Welch MJ. Nucl. Med. Biol. 2004, 31: 133 - For [124I]-FIAU, see:
-
6a
Simoes MV.Miyagawa M.Reder S.Stadele C.Haubner R.Linke W.Lehner T.Epple P.Anton M.Schwaiger M.Bengl FM. J. Nucl. Med. 2005, 46: 98 -
6b
Soghomonyan SA.Doubrovin M.Pike J.Luo X.Ittensohn M.Runyan JD.Balatoni J.Finn R.Tjuvajev JG.Blasberg R.Bermudes D. Cancer Gene Ther. 2005, 12: 101 -
6c
Wen BX.Burgman P.Zanzonico PJ.O’Donoghue J.Cai SD.Finn R.Serganova I.Blasberg R.Gelovani J.Li GC.Ling CC. Eur. J. Nucl. Med. Mol. Imaging 2004, 31: 1530 -
7a
Krynetski EY.Krynetskaia NF.Bianchi ME.Evans WE. Cancer Res. 2003, 63: 100 -
7b
Marcellin P.Mommeja-Marin H.Sacks SL.Lau GKK.Sereni D.Bronowicki J.-P.Conway B.Trepo C.Blum MR.Yoo B.-C.Mondou E.Sorbel J.Snow A.Rousseau F.Lee H.-S. Hepatology 2004, 40: 140 - 8
Baerwolff D. inventors; DD 259803 A1. - 9
Reefschlaeger J.Baerwolff D.Langen P. Acta Virol. 1984, 28: 282 - 10
Degr’eve B.Esnouf R.De Clercq E.Balzarini J. Mol. Pharmacol. 2000, 58: 1326 -
11a
Yu C.-S.Eisenbarth J.Runz A.Weber K.Zeisler S.Oberdorfer F. J. Labelled Compd. Radiopharm. 2003, 46: 421 -
11b
Yu C.-S.Oberdorfer F. Nucleosides, Nucleotides Nucleic Acids 2003, 22: 71 -
11c
Yu C.-S.Oberdorfer F. Synthesis 1999, 2057 -
11d
Yu C.-S.Oberdorfer F. Synlett 2000, 86 -
11e
Yu C.-S.Wu C.-H.Chiang L.-W.Wang R.-T.Wang H.-Y.Yeh C.-H.Lin K.-I. Chem. Lett. 2005, 34: 1390 -
11f
Yu C.-S.Chiang L.-W.Wu C.-H.Wang R.-T.Wang H.-Y.Yeh C.-H. Nucl. Med. Biol. 2006, 33: 367 - 12
Nyffeler PT.Durón SG.Burkart MD.Vincent SP.Wong C.-H. Angew. Chem. Int. Ed. 2005, 44: 192 - 13
Van Steenis JH.van der Gen A. J. Chem. Soc., Perkin Trans. 1 2002, 2117 - 14
Yu C.-S. Thesis Heidelberg University; Germany: 1999.